New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects

Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and an...

Full description

Saved in:

Bibliographic Details
Published in:	Terapevtic̆eskii arhiv Vol. 93; no. 9; pp. 1132 - 1137
Main Authors:	Dragomiretskaya, Natalia A., Tarzimanova, Aida I., Kucherova, Julia S., Podzolkov, Valery I.
Format:	Journal Article
Language:	English Russian
Published:	"Consilium Medicum" Publishing house 15-09-2021
Subjects:	aldosterone antagonists antifibrotic effect arterial hypertension chronic heart failure covid-19 spironolactonum
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).
ISSN:	0040-3660 2309-5342
DOI:	10.26442/00403660.2021.09.201016